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for the intention to use the EMR. For nurses this attribute was followed by support 
from supervisor, presence of performance feedback from the EMR and presence o 
f decisions support. While for physicians this ordering differed since presence of 
decision support was relatively more important than performance feedback and 
support from the supervisor. ConClusions: Considering the prominent wish of all 
the intended users for a flexible interface, currently used EMRs only partially comply 
with the needs of the users, indicating the need for closer incorporation of user 
needs during development stages of EMRs. The differences in priorities amongst 
nurses and physicians show that different users have different needs during the 
implementation of innovations. Hospital management may use this information to 
design implementation trajectories to fit the needs of various user groups.
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objeCtives: To describe the current status of Pharmacoeconomic (PE) research 
in China from Jan 2002 through June 2013. Methods: We conducted a review of 
pharmacoeconomic studies performed in China during Jan 2002 to June 2013. Using 
the Wanfang Chinese Database, we identified a total of 1338 articles. Keywords used 
are ‘Pharmacoeconomics’ or ‘Cost-Effectiveness Analysis’ or ‘Cost-Benefit Analysis’ 
or ‘Cost-Utility Analysis’ or ‘Cost’ or ‘Cost Study’ or ‘Economics Analysis’ all following 
by ‘(Healthcare and Medical Care)’ to exclude animal and other studies. Through a 
manual review, we excluded another 52 articles that did not align with study objec-
tives. Article types selected are Journals, Academic Essays and Conference Essays. 
Descriptive analyses were performed to identify current trends, including number 
of articles by year, type of studies, and type of studies by year. Results: A total of 
1286 articles were conducted in China from 2002 to 2013. In general, the number of 
articles per year has been on the rise since 2002and appears to approach a steady 
state after 2007. Numbers of articles by year are 91 in 2002, 84 in 2003, 107 in 2004, 
110 in 2005, 136 in 2006, 132 in 2007, 121 in 2008, 120 in 2009, 130 in 2010, 116 in 2011, 
112 in 2012 and 27 during first half of 2013. The most common type of studies found 
were economic analyses (n= 908/1286), of which cost-benefit analyses (n= 395) were 
most commonly conducted. Two other common research types included treatment 
use (n= 48) and application of PE (n= 146), namely the role of PE to help determine 
price and inform health care management decisions. ConClusions: The devel-
opment of Pharmacoeconomic research in China has been on a steady rise since 
2002 with most output focused on economic modeling, followed by application of 
PE and treatment use.
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objeCtives: Economic evaluations of interventions in the hospital setting often 
rely on the estimated long-term impact on patient survival. Estimates of mortality 
rates and long-term outcomes among patients discharged alive from the inten-
sive care unit (ICU) are lacking from lower and middle-income countries. This 
study aimed to assess the long-term survival, life expectancy (LE) and the quality-
adjusted life expectancy (QALE) amongst post-ICU patients in a middle-income 
country. Methods: In this retrospective cohort study, data from a regional tertiary 
hospital in northeast Thailand and the regional death registry were linked and used 
to assess patient survival time after ICU discharge. Adult ICU patients aged at least 
15 years who had been discharged alive from an ICU between 1anuary 1, 2004 and 
December 31, 2005 were included in the study, and the death registry was used to 
determine deaths occurring in this cohort up to December 31, 2010. These data 
were used in conjunction with standard mortality life tables to estimate annual 
mortality and LE. Results: A total of 10,321 ICU patients were included in this 
analysis; 3,251 patients (31.5%) died during ICU admission. Of 7,070 patients dis-
charged alive, 2,527 (35.7%) were known to have died within the five-year follow-up 
period, a mortality rate 2.5 times higher than that in the Thai general population 
(age- and sex-matched). The mean LE was estimated as 18.3 years compared with 
25.2 years in the general population. Given the range of the Health Related Quality 
of Life (HRQOL) from the published literature, the mean QALE of post-ICU patients 
would range from 10.2 to 16.1. ConClusions: Post-ICU patients experienced much 
higher rates of mortality than members of the general population over the five-year 
follow-up period, particularly in the first year after discharge. Further work assess-
ing HRQOL in both post-ICU patients and in the general population in developing 
countries is needed.
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Joint commission (JCI) International Patient centered standards-2011 promotes 
improvements in patient safety(ISPG) & Medication Management Use (MMU). 
objeCtives: To investigate historical changes of patient-safety approach in Saudi 
Arabia, create comparison baseline for future studies. Methods: Cross-sectional 
2003 survey sent to pharmacy managers of 127 hospitals of Ministry of Health(MOH); 
67.7% responded; data of 63.7% hospitals were valid for analysis. 19 hospitals were 
chosen deliberately according to their level of development, their data was tested 
against selected criteria. Due to limitations of data; only 2 criteria were selected: 
PHP105
DrivErS of clinician PrEScribing DEciSionS anD tHE EconomicS of 
information
Parkinson B., Viney R., Goodall S., Haas M.
University of Technology, Sydney, Ultimo, Australia
objeCtives: Policy decision makers require accurate forecasts of the financial 
implications of funding a new drug. They may also wish to influence adoption to 
ensure the most cost-effective pattern of care. The seminal theory regarding the 
adoption of innovations was published by Rogers in 1962; but there are several 
reasons why health care may be a special case. This paper assesses the applicabil-
ity of Rogers’s theory to the adoption of new drugs, and identifies how it could 
be extended using economic theories of information. Methods: The empirical 
literature on drug adoption was reviewed to determine the consistency of findings 
with Rogers’s theory and the economic theories of information. Results: Overall 
74 empirical studies were reviewed. Clinicians consider a broad range of attributes 
when adopting a new drug, with their relative importance dependent on the patient 
and therapeutic area. Consistent with Rogers’s theory, interpersonal communication 
channels are the most important information source, with clinicians, especially GPs, 
more likely to rely on advice from specialists or pharmaceutical representatives than 
peer-reviewed publications. Moreover, clinicians are influenced by ‘norm’ prescrib-
ing behaviour. These findings can be further explained using economic theories of 
information. Obtaining information via peer-reviewed publications requires more 
effort compared to specialists and pharmaceutical representatives. As patients can-
not observe the effort expended, there is a potential for moral hazard in terms of 
reduced effort and thus an increased reliance on pharmaceutical representatives. 
Clinical evidence is often uncertain and not always directly applicable to current 
practice, which can lead to following ‘norm’ prescribing behaviour and persistent 
prescribing when combined with risk-aversion. ConClusions: Rogers’s theory 
only partially explains drug adoption. An expanded framework regarding drug adop-
tion is proposed, incorporating agency relationships, moral hazard, uncertainty 
and risk-aversion.
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objeCtives: Medical nutrition is dedicated to patients with some nutritional defi-
ciencies or inability to eat normally. When used on top of normal diet in patients 
or in Crohn’s disease, medical nutrition can improve patient’s recovery or have a 
therapeutic effect. Although efficacy studies of medical nutrition exist, it is unclear 
regarding health economic analysis. This research assessed the current health eco-
nomic evidence published on medical nutrition. Methods: A systematic literature 
search was performed using PubMed, the Health Technology Assessment Database, 
and the NHS Economic Evaluation Database. For selected articles, the clinical back-
ground and basis of the analysis, health economic design and results were extracted. 
Finally for health economic modeling studies, the Drummond checklist was applied 
to validate their quality; whereas for systematic reviews the AMSTAR checklist 
was used. Results: Fifty-three articles were identified and obtained via PubMed. 
Among them, 32 articles have been included in a thorough data extraction proce-
dure. Among these articles, only few health economic models have been found: Most 
of the articles were modelling analyses and economic trials. Overall only 8 health 
economic models were validated applying the Drummond checklist. Anyhow, most 
included models have been carried out with a quite high quality standard even 
though some areas were identified for further improvement. Within the two iden-
tified reviews of health economic studies one review achieved the highest quality 
scores applying the AMSTAR checklist. ConClusions: Reasons for finding only few 
modeling studies but quite a large number of clinical trials with health economic 
endpoints might have different reasons. Until recently, health economics wasn’t 
required in reimbursement or coverage decisions for medical nutrition interven-
tions; and there might be specificities of medical nutrition which might not allow 
easy modeling. Further research is warranted to understand the specifics of medical 
nutrition and its applicability for health economic modelling.
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objeCtives: Electronic medical records (EMRs) in hospitals are potentially ben-
eficial for quality and safety of care, but diffuse slowly. Many of the barriers and 
facilitators of the adoption of EMRs are identified, but the relative importance of 
these factors is still undetermined. This paper quantifies the relative importance 
of known barriers and facilitators of EMR, experienced by the users (i.e., nurses and 
physicians in hospitals). Methods: A d-efficiently designed discrete choice experi-
ment (DCE) was conducted among physicians and nurses. Participants answered ten 
choice sets containing two scenarios. Each scenario included attributes that were 
based on previously identified barriers in the literature and the model of the Unified 
Theory of Acceptance and Use of Technology (UTAUT), namely : data entry hardware, 
technical support, supervisor attitude, performance feedback, flexibility of interface 
and decision support. Panel Mixed Multinomial Logit analysis was used to determine 
the relative importance of the attributes. Results: Data on 148 nurses and 150 phy-
sicians showed that high flexibility of the interface was the most important factor 
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objeCtives: Pharmaceutical full-line wholesalers carry out a variety of main func-
tions. One of these is the financing function. Pharmaceutical full-line wholesal-
ers stock and distribute the complete assortment of products in range and depth. 
Moreover, they acquire ownership over the medicinal products when purchasing 
them from the manufacturers and pass on ownership to pharmacies when they 
are delivered. Thus, the analysis aims to draw a comprehensive picture of the pre-
financing function, expressed in terms of working capital, of the pharmaceutical 
wholesale sector in Europe. Methods: The necessary data was provided by the 
European Association of Pharmaceutical Full-line Wholesalers (GIRP). The study 
analysed core indicators representative for all countries of the European Union 
plus Croatia, Norway and Switzerland (EU-25 + 3), with the exception of Malta and 
Cyprus as no full-line wholesalers are operating in the latter. Results: In the ana-
lysed countries, 935 pharmaceutical full-line wholesalers operate 1,220 warehouses, 
serving 171,767 retail and hospital pharmacies and dispensing doctors and sup-
ply 520 million people. In 2012, pharmaceutical full-line wholesalers generated a 
total turnover of € 130 billion in the EU-25 + 3. Pharmaceutical full-line wholesalers 
assume a pre-financing function towards manufacturers and pharmacies that is 
not offered by other distribution models. In the EU-25 + 3 alone they pre-financed 
on average € 12.2 billion over a period of 35 days. In total, this sum is pre-financed 
approximately ten times per year. ConClusions: Pharmaceutical full-line whole-
salers pre-finance the entire retail market of medicinal products, guarantee the 
continuous supply of all medicinal products and secure the cash flow of social 
insurers. The funding and holding of buffer stocks, the resulting working capital 
and ownership that goes with wholesaling services are vital for an effective and 
efficient functioning of the health care industry in Europe.
PHP115
EStimating markEt PotEntial for bioSimilar introDuction
Paglia R.1, Bache G.2, Rossi C.3
1PAREXEL Consulting, East Brunswick, NJ, USA, 2PAREXEL Consulting, Uxbridge, UK, 3PAREXEL 
INTERNATIONAL, Uxbridge, UK
objeCtives: The global biopharmaceutical industry is facing a biologics “pat-
ent cliff” between 2013 and 2020, which will leave approximately $54 billion in 
drug revenue, without patent protection. In order to achieve success with these 
biosimilar agents, it is critical that manufacturers/marketers target the highest 
potential global markets. The objective of this research is to provide a framework 
for identifying the markets with the highest potential for biosimilar adoption and 
utilization. Methods: A review of literature, research reports, and review articles 
was conducted, along with a panel discussion of industry thought leaders in bio-
similars. Key indicators of biosimilar market potential were identified, evaluated, 
and prioritized. A systematic approach was developed to score each key indicator, 
and a mathematical approach adopted to aggregate the market scores. A series 
of 20 country markets were evaluated and ranked in order of biosimilar market 
potential. Results: Key indicators of biosimilar market potential were separated 
into three categories: 1.) Originator-drug indicators including originator sales, 
reimbursement level, and reimbursement status. 2.) Market indicators including 
rate of uptake of currently available biosimilars, payer cost-containment mecha-
nisms, and future biosimilar outlook. 3.) Regulatory indicators including barriers 
to marketing authorization based on the complexity of required data packages, 
and the risks associated with the development of clinical programs. Secondary 
research of public domain information was conducted on each of 20 countries, in 
order to obtain the data to populate the key indicators for market potential. Each 
country achieved a score based on the data, and was ranked based on biosimilar 
market potential. ConClusions: The process demonstrates a rational approach 
to identifying and sequencing of biosimilar market potential, which can be used to 
inform clinical-development and market-access plans. Also, in practical applica-
tion for a manufacturer/marketer, “resource indicators” of market-specific assets 
should be included.
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objeCtives: To investigate whether trends exist in drug prices of products approved 
by the UK NICE with a Patient Access Scheme in other key EU countries in the last 
2 years. Methods: Expensive new pharmaceuticals that are not deemed cost-
effective by NICE in the first instance, can often still become recommended with 
a Patient Access Scheme. It is a trend that the type of scheme offered is becoming 
purely financial-based, with the last 17 schemes approved offering a simple dis-
count. Although these discounts are ‘commercial in confidence’, the company’s 
willingness to negotiate is obvious. To investigate if NICE recommended drugs with 
simple discount schemes affect pricing elsewhere in Europe, we compared their list 
prices in France, Germany, Italy and the UK. The analysis focused on pharmaceu-
ticals recommended after 1 January 2011. Results: Since 2011, 20 therapies were 
recommended by NICE with a PAS based on a simple discount. In all except one case, 
the UK list price was the lowest among available list prices in all countries analysed. 
Where an Italian list price was available it was usually the highest. When compar-
ing the prices on an ex-manufactory level, the UK prices remain the lowest, but the 
German prices are generally the most expensive in this scenario. Of the countries 
analysed, only Italy has a risk sharing framework in place besides the UK. Out of the 
20 therapies analysed here, only 3 were under an Italian scheme. ConClusions: 
The analysis shows that even before a PAS discount is applied, the UK price is 
already low, usually the lowest in the 4 EU countries analysed. There were no clear 
IPSG.1; identify patients correctly (criteria 1) and MMU.1& MMU.7; identify medi-
cation use & monitoring (criteria 2) Average for conforming to both criteria was 
calculated for each hospital. Correlation was tested between compliance to both 
criteria and hospital characteristics which were hospital type; general/tertiary & 
hospital geographical location; urban/rural. For each criterion; several measurables 
were selected from literature; and their average was calculated accordingly. Criteria 
1; 1 measurable, composed of 2 components of which there average was calcu-
lated. Criteria 2; 2 measurables; measurable for MMU.1 composed of 3 components, 
while measurable for MMU.7 composed of 2 components. Average of averages was 
calculated. Results: A total of 89.47% were complying to criteria 1 &10.53% non-
complying with 10 hospitals 100% conforming. 52.63% were complying to criteria 
2& 47.37% non-complying. Average compliance percentage with criteria 1 was 97.75, 
85.91& 98.25 for general rural, general urban and tertiary urban hospitals respec-
tively. In case of criteria 2, it was 28.75, 27.18& 20.5 for general rural, general urban 
and tertiary urban hospitals respectively. Correlations could not be established, no 
significant difference in means of compliance between or within criteria for dif-
ferent geographical locations or different hospital types; this can be contributed to 
the small sample size. ConClusions: A baseline for comparison of compliance 
to safety-related approach in Saudi Arabia was established which can be used for 
comparison in future studies.
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objeCtives: Serving 172,709 dispensing points, the pharmaceutical wholesale-
industry is a vital branch. One of the major business-objectives is total-customer-
satisfaction. Thus, a questionnaire aimed to draw a comprehensive picture of 
the level of satisfaction (including delivery-times and country-specific-issues) of 
pharmacists with pharmaceutical-full-line and short-line wholesalers, Direct-
sales from manufacturers, Direct-to-Pharmacies (DTP) and Reduced-Wholesale-
Arrangements (RWA) in Europe, focusing on Germany, UK., France, Spain and 
The Netherlands. Methods: The necessary data was obtained from an online-
questionnaire (March 2011-October 2011) which was directed to pharmacies 
(n= 473). Results: The majority of the observed countries (99% in Spain to 72% 
in the UK) of the respondent pharmacists were satisfied with the distribution 
through pharmaceutical-full-line-wholesalers. With regard to the delivery-time 
offered by pharmaceutical-full-line wholesalers the satisfaction ranged from 97% 
in Spain to 76% in the UK. With regard to the distribution through short-line-
wholesalers 62.50% of the German pharmacists were satisfied. With their delivery-
time 56.30% of the pharmacists were satisfied, whereas 50.00% (distribution) and 
38.90% (delivery-time) of the Dutch-participants showed satisfaction. Less than 
half of the respondents (58% in Spain to 12% in the UK) in four out of the five 
countries observed showed satisfaction with the distribution through Direct-sales 
from manufactures. 80% of the pharmacists in the UK were unsatisfied with this 
kind of distribution-system. Concerning the delivery-time pharmacists in the 
majority of the observed countries answered with neutral. Pharmacists in the 
UK (76%) were unsatisfied with Direct-sales from manufacturer. Pharmacists in 
the UK were unsatisfied with Direct-to-Pharmacy and the Reduced-Wholesale-
Arrangements (DTP: 89.70% distribution vs. 75.90% delivery-time; RWA: 90.80% 
distribution vs. 58.50% delivery-time). Country-specific-issues mentioned were 
lack-of-availability of medicinal-products, stock-problems (UK), out-of-stocks 
problems (NL), shortages, supply-problems (ES) and decrease in discount-rates 
(DE). ConClusions: The satisfaction of pharmacists varies greatly between dif-
ferent distribution-models. Responding pharmacists in the countries observed 
receiving their medicinal-products through pharmaceutical full-line-wholesalers 
showed overall-satisfaction with this kind of distribution-system.
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objeCtives: Until March 2013,decisions on Individual funding requests (IFRs) had 
been the job of the primary care trusts to decide upon such requests. It has been 
widely acknowledged that IFRs to fund particular treatments have caused PCTs 
some thorny problems (with the rate of acceptance of IFRs having fallen from 59% in 
2008/09 to 46% in 2010/11). However, with the Clinical Commissioning Groups (CCGs) 
formally assuming commissioning responsibilities for their local populations since 
April 2013, it is expected that health services and care pathways will become more 
patient focussed. The objective of this study was to assess whether IFRs will enjoy 
better success under the so-called ‘patient centred’ CCG leadership. Methods: 
This research was based on a combination of secondary and primary research to 
assess the CCGs attitudes and expertise to cope with IFRs. Secondary research of 
published data such as current IFR policies and overall CCG health care priorities 
contributed towards a framework to understand the key factors affecting success-
ful management of IFRs, which was then validated through a telephone survey 
of health care stakeholders. Results: CCGs understand the importance and the 
value of having a clear and robust IFR policy. Learning from PCTs, CCGs also realise 
that having a clear IFR standard operating procedures and clear timeframes would 
mean spending significantly less time considering and defending decisions on IFRs. 
Some CCGs also believe that public conversation may be required IFRs are to be 
managed effectively. ConClusions: While CCGs realise that IFRs would be one 
of complicated bit of commissioning responsibilities, their real challenge is avoid 
making the same mistakes as PCTs. Early engagement with local populations about 
commissioning priorities is perceived to be crucial. Also the success of IFRs depends 
on organisations such as NHS Clinical Commissioners due to their dual role as CCG 
supporter and a body accountable to government.
